Page last updated: 2024-11-05

6-n-hydroxylaminopurine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(6)-hydroxyadenine : A member of the class of 6-aminopurinnes that is adenine in which one of the exocyclic amino hydrogens is replaced by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID21876
CHEMBL ID393474
CHEBI ID78235
SCHEMBL ID160073
SCHEMBL ID17176886
MeSH IDM0101685

Synonyms (46)

Synonym
ccris 2558
hap (van)
ai3-60188
n(6)-hydroxyadenine
n-hydroxy-1h-adenine
einecs 227-125-5
n-hydroxy-1h-purin-6-amine
nsc 516286
NCI60_004253
6-hydroxylaminopurine
HAP ,
5667-20-9
6-n-hydroxylaminopurine
nsc516286
1h-purin-6-amine, n-hydroxy-
6-(n-hydroxyl)aminopurine
wln: t56 bm dn fn hnj imq
adenine, n-hydroxy-
nsc-516286
6-hydroxyaminopurine
n6-hydroxyadenine
CHEMBL393474
chebi:78235 ,
n-hydroxyadenine
n-(7h-purin-6-yl)hydroxylamine ,
FT-0695180
n-(9h-purin-6-yl)-hydroxylamine
n(6)-hydroxyaminopurine
n(6)-hydroxylaminopurine
AKOS015904882
n-(9h-purin-6-yl)hydroxylamine
n-(7h-purin-6-yl);hydroxylamine
SCHEMBL160073
DTXSID4044959
n-hydroxy-9h-purin-6-amine
J-200190
6-n-hydroxyaminopurine
AKOS025148691
6h-purin-6-one, 1,7-dihydro-, oxime
SCHEMBL17176886
AKOS028109002
Q27147693
BS-52906
6-hap
A924302
CS-0197293

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves showed that AHA and HAP were about equally mutagenic at low doses but that AHA was more mutagenic than HAP at high doses."( Effect of the uvs-2 allele of Neurospora crassa on the mutagenic potency of two N-hydroxylaminopurines and 2-aminopurine in the ad-3 forward-mutation test.
Brockman, HE; de Serres, FJ; Hung, CY; Ong, T, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
teratogenic agentA role played by a chemical compound in biological systems with adverse consequences in embryo developments, leading to birth defects, embryo death or altered development, growth retardation and functional defect.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
6-aminopurinesAny compound having 6-aminopurine (adenine) as part of its structure.
nucleobase analogueA molecule that can substitute for a normal nucleobase in nucleic acids.
hydroxylaminesHydroxylamine, H2N-OH, and its hydrocarbyl derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID300106Selectivity index, ratio of CC50 for human KB cells to IC50 for Plasmodium falciparum 3D72007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID300104Antimalarial activity against chloroquine, pyrimethamine and cycloguanil-resistant Plasmodium falciparum VS1 after 24 hrs2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID300107Selectivity index, ratio of CC50 for human KB cells to IC50 for Plasmodium falciparum K12007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID300110Antiparasitemia activity against Plasmodium berghei infected mice (Mus musculus) at 30 mg/kg peroral dose for 4 days2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID300105Cytotoxicity against human KB cells2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID445485Inhibition of [3H]adenine uptake at rat adenine 1 receptor expressed in human 1321N1 cells at 100 uM after 1 min by liquid scintillation counting2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family.
AID445473Selectivity ratio of Ki for adenine 1 receptor in HEK293 cells to Ki for adenine 1 receptor in rat brain cortical membrane2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family.
AID445467Displacement of [3H]adenine from adenine 1 receptor in rat brain cortical membrane by liquid scintillation counting2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family.
AID300108Selectivity index, ratio of CC50 for human KB cells to IC50 for Plasmodium falciparum VS12007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID300109Antiparasitemia activity against Plasmodium berghei infected mice (Mus musculus) at 30 mg/kg subcutaneous dose for 4 days2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID1367177Binding affinity to 1A1 Bacillus subtilis xpt-pbuX RNA guanine riboswitch2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
RNA as a small molecule druggable target.
AID300103Antimalarial activity against chloroquine,pyrimethamine-resistant Plasmodium falciparum K1 after 24 hrs2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID300102Antimalarial activity against drug-sensitive Plasmodium falciparum 3D7 after 24 hrs2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID445471Displacement of [3H]adenine from adenine 1 receptor in HEK293 cells by liquid scintillation counting2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family.
AID445483Agonist activity at rat adenine 1 receptor expressed in human 1321N1 cells assessed as inhibition of isoproterenol-induced [3H]cAMP formation at 50 uM by scintillation counting relative to adenine2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (53)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (26.42)18.7374
1990's18 (33.96)18.2507
2000's8 (15.09)29.6817
2010's13 (24.53)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.69 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (5.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (94.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]